Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mile High Behavioral Healthcare Transgender Center of the Rockies | UNKNOWN |
| The Gay Lesbian Bisexual & Transgender Community Center of Colorado | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
HIV prevalence among transgender women (TW) in the United States is high (~14%). The best way to reduce HIV incidence in this population is to link TW to HIV pre-exposure prophylaxis (PrEP), which can reduce HIV transmission by up to 86%, with optimal adherence. The FDA approved the first long-acting form of PrEP, injectable cabotegravir (CAB-LA), in late 2021, which has the potential to decrease HIV transmission and increase PrEP adherence among TW. The addition of CAB-LA to available PrEP options necessitates TW and PrEP service providers select the best method (oral vs injectable) for each TW. However, TW have unique concerns about PrEP (e.g., interactions with gender-affirming hormones) and report that patient/provider discussions on this medication are suboptimal. Thus, to inform this shared decision process, the proposed study builds on formative work by developing and pilot-testing "WePrEP," a PrEP-focused bilingual digital shared decision-making tool (SDMT), tailored to diverse English- and Spanish-speaking TW and PrEP service providers. WePrEP will support communication between TW and PrEP service providers as they identify the ideal PrEP product for each TW and discuss associated adherence strategies by cuing conversations on TW's unique PrEP needs/concerns and presenting pertinent information that is culturally relevant and tailored to this population. To develop and test WePrEP, the investigators will partner with the Mile High Behavioral Healthcare Transgender Center of the Rockies, a Denver-based transgender-serving organization. They will use McNulty et al.'s adapted Shared Decision-Making Model for TW to guide the iterative participatory design process we will use with a group of racially/ethnically diverse TW and PrEP service providers, to develop WePrEP; we will begin this process using prototypes created from preliminary data (Aim 1a). The investigators will rigorously assess the usability of WePrEP via simulated patient/provider discussions (Aim 1b). Next, they will pilot test WePrEP in a randomized controlled trial (RCT; N=69 TW) with 2:1 randomization. In the RCT, PrEP service providers (N=4, of which n=1 is bilingual) will use WePrEP with intervention TW to select CAB-LA or oral PrEP and discuss adherence. Other providers (N=2, of which n=1 is bilingual) will give control TW a standard of care explanation of PrEP (CDC recommendations) to help them make their PrEP choice. TW will be referred to Sheridan Health Services to start PrEP. We will assess primary (feasibility; acceptability) and secondary (potential mechanisms of action of WePrEP; preliminary impact) outcome measures using validated scales and rigorous qualitative methods (Aims 2, 3). By creating a bilingual digital SDMT to enhance communication between TW and PrEP service providers as TW choose their ideal PrEP modality, this project is likely to make a widespread and lasting impact on TW's uptake and adherence to PrEP.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group: Transgender women | Experimental | Transgender women randomized to the intervention group will use WePrEP with a PrEP service provider. WePrEP will be stored on providers' tablets and will present oral PrEP and CAB-LA priority information points, identified during preliminary studies, and cue relevant discussions. Once a transgender woman assigned to the control group selects her preferred PrEP method, the provider will review the appropriate adherence strategies using WePrEP. |
|
| Control group: Transgender women | Active Comparator | Transgender women randomized to the Control Group will receive a standard of care PrEP explanation from a PrEP services provider designated to deliver this trial condition. This explanation follows the 2021 CDC PrEP Clinical Guidelines, which have been updated to include information about CAB-LA. |
|
| Intervention group: PrEP service providers | Experimental | During the study, PrEP service providers randomized to the intervention group will use WePrEP with transgender women participants in the intervention group who are potential PrEP patients. WePrEP will be stored on providers' tablets and will present oral PrEP and CAB-LA priority information points, identified during preliminary studies, and cue relevant discussions. Once the participant selects her PrEP method, the provider will review the appropriate adherence strategies. To ensure that they are able to provide feedback on WePrEP in IDIs, intervention group PrEP service providers will use WePrEP with a minimum of 8 different transgender women in this study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| WePrEP: A shared decision-making tool | Behavioral | WePrEP will be bilingual, both patient- and provider-facing, stored on the provider's electronic device (and will have the capability to integrate with electronic health records in the future to enable scalability), and easily accessible during in-person or virtual patient-provider encounters. WePrEP is designed to present pertinent PrEP information to transgender women and their PrEP service providers to stimulate discussions about PrEP choice and support adherence (once a PrEP strategy has been chosen). We hypothesize that this will ensure selection of the ideal PrEP method and improve subsequent adherence. |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility | Feasibility of Intervention Measure (FIM) [Range: 1-5; Higher scores mean greater feasibility] | At enrollment |
| Acceptability | Acceptability of Intervention Measure (AIM) [Range: 1-5; Higher scores mean greater acceptability] | At enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Preliminary impact (1st of 3 measures) | Proportion of transgender women who receive their first dose of either form of PrEP (measured at enrollment). | The proportion of transgender women who receive either form of PrEP is measured at enrollment. |
| Preliminary impact (2nd of 3 measures) |
Not provided
Inclusion Criteria:
Eligible participants in the transgender women group (N=69) must:
Eligible participants in the PrEP service providers group (N=6) must:
Exclusion Criteria:
Participants in the transgender women group are excluded if they:
Participants in the PrEP service providers group are excluded if they:
Transgender women: defined as people assigned male at birth, but have a current feminine gender identity
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christine T Rael, PhD | Contact | 303-734-8541 | christine.rael@cuanschutz.edu | |
| Samantha Stonbraker, PhD | Contact | 303-724-8281 | samantha.stonbraker@cuanschutz.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Transgender Center of the Rockies | Recruiting | Sheridan | Colorado | 80110 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Control group: PrEP service providers | Active Comparator | PrEP service providers randomized to the Control Group will give transgender women enrolled in this study a standard of care PrEP explanation. This explanation follows the 2021 CDC PrEP Clinical Guidelines, which have been updated to include information about CAB-LA. |
|
|
| Active comparator: CDC recommendations for discussing PrEP | Behavioral | Standard of care recommendations to discuss PrEP with potential end-users, endorsed by the CDC. |
|
Proportion of transgender women who have a high enough serum concentration of either form of PrEP to prevent HIV at the second dose (measured at follow-up). |
| For oral PrEP: PrEP serum concentrations are measured at 3 months. For injectable PrEP: PrEP serum concentrations are measured at 2 months. |
| Preliminary impact (3rd of 3 measures) | Proportion of transgender women who refill (oral PrEP) or take an injection (injectable PrEP) at the second dose (measured at follow-up). | For oral PrEP: PrEP refills are measured at 3 months. For injectable PrEP: Injections are measured at 2 months. |
| Mechanisms of action: Patient/provider communication (1st of 7 measures) | Communication composite measure from the Consumer Assessment of Healthcare Providers & Systems (CAHPS) [Range: 1-4; Higher scores mean better communication] | Measured at enrollment |
| Mechanisms of action: Satisfaction with communication (2nd of 7 measures) | Combined Outcome Measure for Risk Communication and Treatment Decision-making Effectiveness (COMRADE) [Range: 1-5 where higher scores mean greater satisfaction] | Measured at enrollment |
| Mechanisms of action: Patient/provider engagement (3rd of 7 measures) | Engagement with Health Care Providers (HCP) scale [Range: 1-5, where higher scores mean greater engagement] | Measured at enrollment |
| Mechanisms of action: Evidence of shared decision-making (4th of 7 measures) | Control Preferences Scale (CPS) - domain measuring actual control over decision [Range: 1-5, where higher scores mean greater control] | Measured at enrollment |
| Mechanisms of action: Satisfaction with control over PrEP decision (5th of 7 measures) | Control Preference Scale (CPS) - domain measuring control satisfaction [Range: 1-5, where higher scores mean greater satisfaction] | Measured at enrollment |
| Mechanisms of action: Knowledge, motivation and self-efficacy to use PrEP (6th of 7 measures) | PrEP Knowledge, Motivation, & Self-Efficacy Assessment [Range: 1-5, where higher scores mean greater knowledge, motivation, and self-efficacy] | Measured at enrollment |
| Mechanisms of action: Satisfaction with PrEP choice (7th of 7 measures) | Treatment Satisfaction Questionnaire [Range: 1-5, where higher scores mean greater satisfaction] | Measured at follow-up (for oral PrEP users, this is at 3 months; for injectable PrEP users, this is at 2 months) |